Condition: Status Epilepticus · Sponsor: Erasme University Hospital
SENSE-II/AROUSE is a prospective, multicenter registry for patients treated for SE. The primary objective is to document patients and SE characteristics, treatment modalities, EEG features, and outcome of consecutive adults admitted fir SE treatment in each of the participating centers and to identify predictors of outcome and refractoriness.
This description comes directly from the study's public registry record.
Nicolas Gaspard, MD, PhD · 00325553429 · Nicolas.Gaspard@erasme.ulb.ac.be
Charlotte Damien, MD · 00325553429 · Charlotte.Damien@erasme.ulb.ac.be
Always discuss trial participation with your own doctor first.
| Kepler University Linz | Linz, Austria | Not Yet Recruiting |
| Christian Doppler Klinik of Paracelsus Medical University | Salzburg, Austria | Not Yet Recruiting |
| HUB Erasme | Brussels, Belgium | Recruiting |
| Odense University Hospital & Svenborg Hospital | Odense, Denmark | Recruiting |
| Helsinki University Central Hospital | Helsinki, Finland | Not Yet Recruiting |
| Goethe-Universität Frankfurt am Main | Frankfurt, Germany | Not Yet Recruiting |
| Epilepsy Center Münster-Osnabrück, Klinikum Osnabrück | Osnabrück, Germany | Not Yet Recruiting |
| Oslo University Hospital | Oslo, Norway | Not Yet Recruiting |
| University Hospital Basel | Basel, Switzerland | Not Yet Recruiting |
| University Hospital of Geneva | Geneva, Switzerland | Not Yet Recruiting |
| Birmingham University Hospitals NHS Trust | Birmingham, United Kingdom | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05839418